General Information of Drug (ID: DMAIS1D)

Drug Name
3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol Drug Info
Synonyms CHEMBL43742; 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol; SCHEMBL7458088; ZINC13835547; BDBM50070645; (2S,3R)-3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10593196
TTD Drug ID
DMAIS1D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Adenosine deaminase (ADA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cladribine DM3JDRP Hairy cell leukaemia 2A82.2 Approved [2]
Elapegademase DMS7OU8 Adenosine deaminase defciency 4A01.1 Approved [3]
Fludarabine DMVRLT7 Acute myelogenous leukaemia 2A41 Approved [4]
Pentostatin DM0HXDS Acute graft versus host disease 4B24.0 Approved [4]
GSK2696273 DMP5O1U Chronic pain MG30 Preregistration [5]
OTL-101 DMLMS6J Severe combined immunodeficiency 4A01.10 Phase 3 [6]
Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy DMIREUZ Immunodeficiency 4A00-4A85 Phase 1/2 [5]
EHNA DM014WS Discovery agent N.A. Investigative [7]
3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol DMZT8QX Discovery agent N.A. Investigative [1]
1-Deaza-Adenosine DMG0VN6 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [1]

References

1 Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
2 Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline.
6 Clinical pipeline report, company report or official report of Orchard Therapeutics.
7 Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.